There is a controversy whether statins are beneficial in patients with heart failure or not. Trials in which lipophilic statins have been used revealed positive results, unlike major studies where hydrophilic statins were administered. This trial is designed to compare the effects of lipophilic versus hydrophilic statin use in patients with heart failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
85
Atorvastatin administered as well as standard heart failure therapy
Rosuvastatin administered as well as standard heart failure therapy
standard heart failure therapy
Ain Shams University Hospital Cardiology Rehab Unit
Cairo, Egypt
Left Ventricular Ejection Fraction (LVEF)
Time frame: 6 months
Left Ventricular End-diastolic volume (LVEDV)
Time frame: 6 months
Left Ventricular End-systolic volume (LVESV)
Time frame: 6 months
cardiac markers
NT pro BNP (N-terminal prohormone of brain natriuretic peptide) sST2 (soluble suppression of tumorigenicity 2)
Time frame: 6 months
Minnesota Living with Heart Failure Questionnaire( MLHFQ)
Time frame: 6 months
Packer composite outcome
* Patients are considered improved if at the final visit they experienced a favorable change in NYHA functional class or in the patient global assessment: markedly/moderately improved (or both) but did not experience any major adverse clinical events during the course of the trial (death or hospitalization). * Patients are considered worse if they experienced a major clinical event during the duration of treatment or reported worsening of their NYHA class or global assessment at the final visit. * Patients are considered unchanged if they are neither improved nor worse.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.